Skip to main content

05-06-2020 | EULAR 2020 | Conference coverage | Video

Researcher comment: SELECT-PsA-1

Frank Behrens discusses the findings from a phase 3 trial comparing upadacitinib with placebo and adalimumab in patients with psoriatic arthritis and an inadequate response to non-biologic DMARDs (7:48).

Read the transcript

Related content

05-06-2020 | EULAR 2020 | Conference coverage | News

Upadacitinib shows promise for PsA

06-06-2020 | EULAR 2020 | Conference coverage | Video

Researcher comment: SELECT-PsA-2